This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MLV Announces Formation Of Advisory Board And Appointment Of Dr. Rahul Singhvi As Its Founding Director

Prior to joining Novavax in 2005, Dr. Singhvi served in a number of positions at Merck & Co., where he helped develop several vaccines, including Zostavax®, the only vaccine on the market to prevent shingles.

In 2010, The Daily Record in Maryland recognized Dr. Singhvi as one of the most influential Marylanders in the healthcare field.  In that same year, during Dr. Singhvi's tenure as CEO, Novavax was named as one of the ten most innovative companies in the biotechnology industry by Fast Company magazine.  Dr. Singhvi has participated in the Clinton Global Initiative and serves on the Board of Directors of Immunocellular Therapeutics, a US public company working on cancer vaccines.

Dr. Singhvi graduated with a chemical engineering degree from the Indian Institute of Technology (IIT), Kanpur, India, where he was top-ranked chemical engineer in his class.  He received both his M.S. and Sc.D degrees in chemical engineering from MIT and an MBA from the Wharton School of the University of Pennsylvania where he graduated as a Palmer Scholar.

ABOUT MLV:

MLV is a boutique investment bank and institutional broker-dealer focused on providing independent financial advice and unique capital markets expertise to corporate and institutional clients in capital intensive industries.  With a focus on raising money efficiently for clients, MLV has rapidly become a leader in the At-the-Market (ATM) transaction market.  Please visit our website:   www.mlvco.com.

For further information please contact: Randy Billhardt: (212) 542-5882 ( rbillhardt@mlvco.com)Member FINRA, SIPC.

SOURCE McNicoll, Lewis & Vlak LLC

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs